Background Patients with schizophrenia are a high-risk population due to higher prevalences of cardiovascular risk factors and comorbidities that contribute to shorter life expectancy.
Purpose To investigate patients with and without schizophrenia experiencing an acute myocardial infarction (AMI) in relation to guideline recommended in-hospital management, discharge medications and 5-year major adverse cardiac events (MACE: composite of all-cause mortality, rehospitalisation for reinfarction, stroke or heart failure).
Methods All patients with schizophrenia who experienced AMI during 2000–2018 were identified (n=1008) from the nationwide Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry and compared with AMI patients without schizophrenia (n=2 85 325). Kaplan-Meier survival curves and multivariable Cox regression models were used to compare the populations.
Results Patients with schizophrenia presented with AMI approximately 10 years earlier (median age 64 vs 73 years), and had higher prevalences of diabetes, heart failure and chronic obstructive pulmonary disease. They were less likely to be invasively investigated or discharged with aspirin, P2Y12 inhibitors, ACE inhibitors/angiotensin II receptor blockers, beta-blockers and statins (all p<0.005). AMI patients with schizophrenia had higher adjusted risk of MACE (aHR=2.05, 95% CI 1.63 to 2.58), mortality (aHR=2.38, 95% CI 1.84 to 3.09) and hospitalisation for heart failure (aHR=1.39, 95% CI 1.04 to 1.86) compared with AMI patients without schizophrenia.
Conclusion Patients with schizophrenia experienced an AMI almost 10 years earlier than patients without schizophrenia. They less often underwent invasive procedures and were less likely to be treated with guideline recommended medications at discharge, and had more than doubled risk of MACE and all-cause mortality. Improved primary and secondary preventive measures, including adherence to guideline recommendations, are warranted and may improve outcome.
- coronary artery disease
- acute coronary syndrome
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
What is already known about this subject?
Patients with schizophrenia are a high-risk population with increased mortality, mainly attributed to cardiovascular diseases because of highly prevalent modifiable cardiovascular risk factors.
What does this study add?
A nationwide analysis of the major adverse cardiac events after acute myocardial infarction (AMI) in a population with schizophrenia, using the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) registry. Our study indicates that the use of guideline recommended therapy in this population following discharge is lower than in patients without schizophrenia, contributing to the worse outcome seen in this population.
How might this impact on clinical practice?
Our results highlight the extent of risk patients with schizophrenia have after an AMI and that they are treated to a lower extent with guideline-based medications. We argue that a multidisciplinary approach should be considered to improve risk factor control, guideline-based treatment and outcome in this high-risk population.
Patients with schizophrenia constitute a high-risk population partially attributed to increased prevalence of cardiovascular risk factors such as diabetes, hypertension, metabolic syndrome, smoking as well as unhealthy eating habits and low physical activity compared with the general population.1–3 Cardiovascular disease is the leading cause of death in patients with schizophrenia, accounting for far more deaths than suicide.4 Schizophrenia is accompanied by a twofold to threefold increased risk of the two most frequent cardiovascular death causes, coronary heart disease (CHD) and cerebrovascular disease, compared with the general population and half of the deaths from CHD are caused by acute myocardial infarctions (AMI).5 6 Notably, several studies have concluded that patients with schizophrenia receive suboptimal preventive and cardiac care despite being at such high risk.7–10 Furthermore, the use of atypical antipsychotic medications also contributes to the development of metabolic syndrome and consequently increases the risk of cardiovascular disease.11
Despite the increased interest in this topic, there is a lack of comprehensive studies of the schizophrenia population with regards to comorbidities, in-hospital treatment, discharge medications and outcomes following AMI in contemporary nationwide study samples. The aim of this study was therefore to describe characteristics of, and the use of guideline recommended secondary preventive medications at discharge and 5-year risk of major adverse cardiac events (MACE: all-cause mortality, rehospitalisation for AMI, hospitalisation for stroke or heart failure) in patients with and without schizophrenia experiencing an AMI.
This nationwide observational follow-up study included all patients aged ≥18 years with a ST-segment elevation MI (STEMI) or non-STEMI (NSTEMI) diagnosis between 1 January 2000 and 29 May 2018 and registered in the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) registry. The patient cohort was divided into patients with and without a schizophrenia diagnosis. The STEMI and NSTEMI diagnoses were determined clinically, and only those with a final discharge diagnosis (I21.0–I21.4), defined by the WHO’s 10th version of International Classification of Disease (ICD-10) diagnosis codes, were included in the study. Schizophrenia was defined as having an ICD-9 code of 295 (used in 1987–1996) or an ICD-10 diagnosis code (used from 1997 and onwards) of schizophrenia (F20) or schizoaffective disorder (F25) at an outpatient visit or in-hospital admission before the index AMI event.
SWEDEHEART contains information on risk factors, medical history, cardiac procedures, treatments during hospitalisation and discharge medications. Using the unique personal identification number given to each citizen in Sweden, the SWEDEHEART registry was linked to the National Population Register and National Patient Registry to obtain further information such as date of death, schizophrenia diagnoses and other non-cardiac comorbidities.12 All personal identification numbers were replaced with an unique SWEDEHEART number to ensure anonymity.
The primary outcome was a 5-year composite MACE comprised all-cause mortality, rehospitalisation for AMI, hospitalisation for stroke or heart failure. The secondary outcomes were the individual components of MACE and bleeding requiring hospitalisation (fatal, cerebral or bleeding requiring surgery or transfusion, defined by ICD-9 (430, 431, 432, 578, 285B, 456A, 531A, 531C, 531E, 531G, 532A, 532C, 532E, 532G, 533A, 533C, 533E, 533G, 534A, 534C, 534E, 534G and 569D) and ICD-10 (I60, I61, I62, D629, I850, K226, K250, K252, K254, K256, K260, K262, K264, K266, K270, K272, K274, K276, K280, K282, K284, K286, K290, K625, K920, K921 and K922) codes) at 5 years following discharge. Other investigated secondary outcomes were proportion treated with guideline recommended discharge medications, patient and system delays and length of hospital stay during hospitalisation for AMI. Length of hospital stay was measured from admission time to discharge time. Patient delay was measured as the time from symptom onset to ECG measurement, a surrogate for first medical contact and system delay was measured from first medical contact to percutaneous coronary intervention (PCI).
Continuous variables are expressed as means with SD or medians with 1st–3rd quartiles and categorical variables as counts with percentages. Differences in baseline variables between the populations were analysed using Mann-Whitney U tests and Student’s t-test for continuous variables and χ2 tests for categorical variables. Time-to-event outcomes were analysed and compared using the Kaplan-Meier survival estimator and log-rank tests as well as univariable and multivariable Cox proportional hazard models, presented as HRs with 95% CIs. The results are presented in four different models, the first model represents the crude HR, the second model adjusted for age and sex and the third model adjusted for age, sex, previous procedures and comorbidities (previous PCI, previous coronary artery bypass grafting (CABG), previous AMI, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disease (COPD), peripheral artery disease, previous bleeding requiring hospitalisation (defined as the bleeding outcome described earlier), stroke, diabetes, hypertension, hyperlipidaemia and smoking status). The fourth model additionally adjusted for revascularisation method during hospitalisation (PCI, CABG or medical management) and guideline recommended discharge medications (ACE-inhibitors or angiotensin II receptor blockers (ARBs), beta-blockers, statins, aspirin and P2Y12 inhibitors). Regression analyses in the final model only included hospital survivors. For the outcome MI, we used a 30-day blanking period as any early readmissions (follow-up visit or readmission) within 30 days from the index event may be incorrectly registered as a reinfarction in the database, for example, due to transfers between hospitals or coding practices. To prevent bias due to the long inclusion period and improvement of treatment over time we performed a sensitivity analysis including year of MI in the final regression model of MACE. Guideline recommended medications were additionally analysed using multiple logistic regressions adjusting for baseline characteristics, as described in the third model. All p values were two-tailed and a value <0.05 was considered statistically significant. Statistical analyses were performed using STATA V.14.0 and SPSS V.25.
The baseline characteristics of the cohort are outlined in table 1. Patients with schizophrenia (n=1008) were younger than those without schizophrenia (n=285 325) (median 64 vs 73 years) at the time of the AMI, less likely to be under employment and more often on sick leave (all p value <0.001). Patients with schizophrenia were also more often current smokers and fewer had never smoked (p value <0.001). They also had a higher prevalence of diabetes, heart failure, COPD and previous bleeding but a lower prevalence of hypertension, chronic kidney disease and peripheral artery disease. Patients with schizophrenia also had fewer previous PCI and CABG performed despite not having fewer previous myocardial infarctions.
Clinical presentation during hospitalisation for AMI are shown in tables 2 and 3. Patients with schizophrenia had higher creatinine, triglyceride and CRP levels, and lower cholesterol levels compared with the population without schizophrenia. They also had lower systolic blood pressure, higher heart rates and more often presented with dyspnoea and cardiac arrest, as opposed to chest pain which was the most common symptom in the non-schizophrenia population. Sinus rhythm as well as left and right bundle branch blocks and pathological Q waves were more common in the schizophrenia population, while their ECG less often showed atrial fibrillation or flutter compared with patients without schizophrenia. Furthermore, a worse left ventricular function was seen in the schizophrenia population. During hospitalisation fewer patients with schizophrenia received a coronary angiography, PCI or CABG.
No statistical differences were seen between the populations in the patient delay; measured from symptom onset to ECG, or system delay; measured from ECG to PCI, neither for the STEMI nor NSTEMI group (table 3). Patients without schizophrenia were hospitalised for a median of 4 days (25th–75th percentiles 4–7) and patients with schizophrenia were hospitalised for a median of 5 days (25th–75th percentiles 4–7), this difference was statistically significant (table 3).
Patients with schizophrenia were less likely to be discharged with aspirin, P2Y12 inhibitors, ACE-inhibitors/ARBs, beta blockers and statins (all p values <0.005; table 4). Following multiple logistic regression adjusting for age, sex and comorbidities (table 5), schizophrenia was independently associated with lower prescription rates of ACE-inhibitors/ARBs (OR 0.66, 95% CI 0.47 to 0.93) and statins (OR 0.3, 95% CI 0.25 to 52).
The clinical outcomes following AMI are shown in table 6 and figure 1. Patients with schizophrenia had higher occurrence of MACE with an unadjusted HR of 1.35 (95% CI 1.23 to 1.47). After adjustment for age and sex in model 2 the HR increased to 2.44 (95% CI 2.23 to 2.67). Further adjustments for comorbidities in model 3 slightly decreased the HR to 2.20 (95% CI 1.79 to 2.71) and additional adjustments for revascularisation method and discharge medications in the final model 4 resulted in a HR of 2.05 (95% CI 1.63 to 2.58). The unadjusted HR for mortality in model 1 was 1.44 (95% CI 1.31 to 1.59), after adjustments the HR in model 2 was 2.99 (95% CI 2.72 to 3.29), in model 3: 2.53 (95% CI 1.00 to 3.21) and in model 4: 2.38 (95% CI 1.84 to 3.09), respectively. The HR for heart failure was increased for patients with schizophrenia in all models; the unadjusted HR in model 1 was 1.25 (95% CI 1.10 to 1.42), model 2 HR 2.14 (95% CI 1.88 to 2.42), model 3 HR 1.49 (95% CI 1.13 to 1.98) and model 4 HR 1.39 (95% CI 1.04 to 1.86). For reinfarction, stroke and bleeding a difference between the populations was only seen in model 2, with HR of 1.53 (95% CI 1.25 to 1.89) for reinfarction, 1.67 (95% CI 1.29 to 2.17) for stroke and 1.55 (95% CI 1.23 to 1.95) for bleeding in patients with schizophrenia.
Additionally adjusting for inclusion year did not alter the results in the final model 3 of MACE: HR 2.08 (95% CI 1.67 to 2.60).
The primary findings of this nationwide study were as follows. Patients with schizophrenia presented approximately 10 years earlier with AMI, but had an increased absolute risk for MACE (all-cause mortality, reinfarction, stroke or heart failure), all-cause death and heart failure, within 5 years, compared with patients without schizophrenia. After adjustments for multiple confounders, patients with schizophrenia had a more than doubled risk of MACE and mortality after AMI, compared with patients without schizophrenia.
We found large outcome differences in relation to schizophrenia; after adjustments for age and sex, we found that patients with schizophrenia had an increased risk of the composite endpoint MACE and all individual endpoints. After further adjustment for comorbidities and treatment the HR remained more than double for MACE and mortality and almost one and a half times higher for heart failure. In a comparable study conducted in Denmark1 investigating MACE following acute coronary syndrome in patients with schizophrenia, the researchers found an increased risk of MACE and all-cause mortality, and additionally an increased risk of stroke. Nonetheless, MACE was comprised fewer variables and the adjustment models were different in the Danish study. In a systematic review13 of mortality in 37 studies found the standard mortality rate in schizophrenia to be 2.58, which corresponds with the increased risk found in our study. A large scale meta-analysis by Correll et al6 investigating cardiovascular disease in patients with severe mental illness likewise corroborates the association between increased risk of heart failure and schizophrenia seen in our study.
As previously discussed, the increased risks can be attributed to multiple mechanisms, among these an increased prevalence of various comorbidities in the population with schizophrenia. Interestingly, in our study we only found increases in baseline prevalences of smoking, diabetes, heart failure, COPD and previous bleeding and a lower prevalence of hypertension. Furthermore, patients with schizophrenia more frequently demonstrated sinus rhythm and pathological Q waves on ECGs, which is in line with previous work.14 15 The latter may not only be indicative of prior recognised MI but also of unrecognised MI or missed STEMI, which is further supported by the fact that patients with schizophrenia in our study more frequently presented with atypical AMI symptoms (ie, dyspnoea) rather than typical (ie, chest pain).
Results regarding comorbidities in AMI patients with schizophrenia varies as some studies show an increased prevalence of hypertension and hyperlipidaemia,16 17 and other studies show lower prevalences of hypertension and hyperlipidaemia.1 18 The variation may perhaps be attributed to dissimilarity in population size and inclusion criteria or under-diagnosis of somatic comorbidities.19 An alternative reason can be the lower awareness of comorbidities found in patients with schizophrenia20 which may impede care and consequently contribute to the increased MACE presented in this study. Yet another factor which could contribute is physician bias in deprioritising patients with schizophrenia during a myocardial infarction. However, in this study we found a homogeneity in system and patient delay between the populations and a longer LOS in patients with schizophrenia following myocardial infarction, ruling out these variables as contributing factors to the increased MACE. Finally, we found patients with schizophrenia to more often present with cardiac arrest, worse ventricular function during hospitalisation and they less often underwent coronary angiography, PCI and CABG during hospitalisation. Adjustment for these variables only slightly attenuated the association between schizophrenia and poor outcome, indicating that other factors remain highly influential.
Following the AMI, there were additional dissimilarities as patients with schizophrenia were less likely to receive any of the recommended guideline medications during discharge: aspirin, P2Y12 inhibitors, ACE-inhibitors/ARBs, beta blockers and statins. This was further confirmed after adjusted multiple logistic analysis which showed ACE-inhibitors/ARBs and statins to be prescribed less frequently. These results are in accordance with a study by Mitchell et al21 investigating prescription of medication in severe mental illness, where they presented evidence for lower than expected rates of prescription of ACE-inhibitors/ARBs, beta blockers and statins for patients with schizophrenia. A Danish study by Kugathasan et al22 investigating the association between secondary preventive treatment after AMI and mortality found scarcer redeemed prescription of guideline recommended medications in a population with schizophrenia, and concluded cardioprotective treatment following AMI to be fundamental in decreasing cardiovascular mortality in this group, underlining the importance of ensuring patients receive guideline recommended medications following AMI.
This study found an increase of MACE at 5 years and evidence of fewer guideline recommended prescriptions following AMI. The mechanisms to why these patients experience worse outcome are many, but some may be modifiable. Improved guideline recommended treatment is essential and should not be overlooked in patients with schizophrenia. More importantly, primary preventive strategies should be introduced in early stages of these patients’ lives and the authors of this study suggest a multidisciplinary approach with improved collaboration between psychiatrists, cardiologists and other involved disciplines in order to combat the poor outcome seen in this high-risk patient population.
First, we included patients over a period of 18 years, in which both the treatment options and guideline recommendations have changed. We accounted for the possibility of time bias by adjusting for year of AMI in a sensitivity analysis, which did not alter the results. Second, the patients with schizophrenia in our study were almost 10 years younger; whether this is attributable to patient selection, that is, older patients with schizophrenia are perhaps more conservatively managed and not treated in coronary care units or catheterisation labs, thus causing an under-representation in the SWEDEHEART registry, or a reflection of a greatly accelerated atherosclerotic cardiovascular disease process will have to be furtherly investigated in future studies. Finally, this was a register-based observational study with known inherent limitations such as risk of selection bias and confounding by indication, making causal conclusions uncertain, as well as potential underdiagnosis and misclassification of ICD-codes resulting in an underestimated prevalence. The 30-day blanking period of MI applied to avoid misclassification of reinfarctions could further contribute to this limitation, however, not blanking the period could have incorrectly inflated reinfarction rates.
Patients with schizophrenia experienced an AMI almost 10 years earlier than patients without schizophrenia. They less often underwent invasive procedures and were less often treated with guideline recommended medications at discharge, and had more than doubled risk of MACE and all-cause mortality. Improved primary and secondary preventive measures, including adherence to guideline recommendations, are warranted and may improve outcome.
Presented at Parts of the results have previously been presented in poster format at the European Society of Cardiology Congress.
Contributors RA designed the study, developed the protocol and analysis plan as well as performed the statistical analyses. RA, AW, SE, TJ, DE, CP and PA interpreted the results and provided feedback. RA wrote the first draft of the manuscript which was shaped by the critical revision of all coauthors. All authors approved the final version suitable for publication.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval The study was approved by the Swedish Ethical Review Authority at Lund University. There was no patients nor public involvement in this study. No patients consent was required for publication due to anonymisation.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. All patients were deidentified upon inclusion.